Nanotechnology mediated drug delivery has been reported to enhance the drug efficacy, bioavailability, reduce toxicity and improve patient compliance by targeting the cells and tissues to produce desired pharmacological action. Aim: The purpose of the present study was to formulate and evaluate rivastigmine loaded chitosan nanoparticles for sustained release. Methods: Rivastigmine is a short ac...

In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24-week double-blind placebo-controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double-blind trial, all patients were permitte...

Rivastigmine, an anti-Alzheimer’s drug, is effective in the treatment of mild to moderate dementia. Oral immediate release (IR) formulation suffers from limitation like severe GI adverse effects which may even result in treatment interruption, like vomiting, diarrhea and anorexia resulting in wide fluctuations in drug plasma levels and calling for altered frequency of dosing. Even the Novel Dru...

BACKGROUND Rivastigmine enhances cholinergic activity and has been shown in clinical trials to decrease the rate of deterioration in Alzheimer's disease. It remains unclear where in the brain it exerts its effect. Functional magnetic resonance imaging (fMRI) can be used to measure changes in brain function and relate these to cognition. OBJECTIVES To use fMRI to study brain activation with ri...

BACKGROUND As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer's disease (AD) in 64 countries. METHODS This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and tolerability of the 5-cm(2) (9-mg loading dose; 4.6 mg/24 h delivery rate) and 10-cm(2) (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine pat...

INTRODUCTION Rivastigmine, a treatment for mild to moderate Alzheimer disease (AD), is the first cholinesterase inhibitor to be available in the transdermal format. We aim to describe user experience and satisfaction with the rivastigmine patch, as well as any clinical changes perceived in patients. METHODS Observational, cross-sectional, multicentre study with 239 investigators and 1851 info...

Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently being used to treat patients suffering from Alzheimer's disease. We have studied the neuroprotective effects of these drugs, in comparison with nicotine, on cell death caused by beta-amyloid (Abeta) and okadaic acid, two models that are relevant to Alzheimer's patholo...

PURPOSE Among the medications approved for Alzheimer's disease (AD), rivastigmine is the only one available as transdermal patch. The aim of this study was to evaluate compliance and caregivers' preference with oral and transdermal (rivastigmine) monotherapy in patients with mild-to-moderate AD from Taiwan. METHODS Real-world Evaluation of Compliance And Preference in Alzheimer's disease trea...

A simple and reproducible HPLC method with spectrophotometric detection was developed for determination of rivastigmine in human plasma. Liquid-liquid extraction of rivastigmine and donepezil (as internal standard) from plasma samples was performed with 1-butanol/n-hexane (2:98 v/v) in alkaline condition followed by back-extraction into diluted acetic acid. Chromatography was carried out using ...